Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.
about
FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl ratsEndoplasmic reticulum stress effector CCAAT/enhancer-binding protein homologous protein (CHOP) regulates chronic kidney disease-induced vascular calcification.Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcificationIncreased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cellsNuclear receptors in renal diseaseFarnesoid X receptor represses hepatic human APOA gene expression.Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imagingSaturated phosphatidic acids mediate saturated fatty acid-induced vascular calcification and lipotoxicity.Liver X receptor-activating ligands modulate renal and intestinal sodium-phosphate transporters.The role of nuclear receptors in the kidney in obesity and metabolic syndromeFarnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.Bile acids regulate cardiovascular functionPERK-eIF2α-ATF4-CHOP signaling contributes to TNFα-induced vascular calcification.Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD.Activating transcription factor 4 regulates stearate-induced vascular calcification.Update on cutaneous calciphylaxis.Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damageActivating transcription factor-4 promotes mineralization in vascular smooth muscle cells.Glycosaminoglycan overproduction in the aorta increases aortic calcification in murine chronic kidney disease.Role of Bile Acid-Regulated Nuclear Receptor FXR and G Protein-Coupled Receptor TGR5 in Regulation of Cardiorenal Syndrome (Cardiovascular Disease and Chronic Kidney Disease)Reduction of inorganic phosphate-induced human smooth muscle cells calcification by inhibition of protein kinase A and p38 mitogen-activated protein kinase.FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver.Farnesoid X receptor regulates vasoreactivity via Angiotensin II type 2 receptor and the kallikrein-kinin system in vascular endothelial cells.Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?The CDK9-cyclin T1 complex mediates saturated fatty acid-induced vascular calcification by inducing expression of the transcription factor CHOP
P2860
Q27329677-DD6FD43F-C7BC-4B7C-B7A3-D342EBDA0E77Q30618674-A9DAA52D-2F84-4386-8912-EF0CC382423AQ34215923-3C4D327A-E29A-4447-9933-64F9492EFB82Q35083231-230DCB0C-7F0A-436C-AEF7-520D30BC197AQ35085053-1E048F7E-8557-4550-8A3B-8094F12F91BCQ35120702-F1806745-DF0A-442B-AD56-AEEF444B927EQ35187047-EA7D4D8F-96A4-4436-8D19-B75E5C06DF4CQ35561963-66353756-2D0C-4372-A743-747CB11C4C51Q35827400-D7949CB0-1CFC-44B4-8557-CD43E85F9309Q36191156-D3C1833C-FA40-4995-A52C-62BF1BE6EA84Q36250127-BF491188-E22F-4A27-8A9F-9BA7B77BA5E4Q36518342-547018B5-C1D7-4686-BF7E-259393E2E05CQ36995617-17B797DA-40E7-43A8-B343-0F013EE27263Q37328721-D9EE92CF-AA00-48DC-8A60-61F2648A6C16Q38628414-B92C59AD-F60E-4A3F-B7B1-BB608A7BD37CQ39342355-34B987DF-B078-44A7-8ADE-52D8C11CA232Q40806798-9E4F04BA-1B5B-4EC6-B6FF-E1BF8F79EEB0Q41550270-072F3E10-C600-4D0C-BF8F-E15C21CE49D3Q41612860-22D7DEFF-2CF9-44DB-B8F0-E342080FF7A4Q41765326-FB756A25-5A3C-4382-A50B-A94EA623D594Q42255441-7B2C38ED-AB76-4872-BBBA-8FD4B6C0A1CCQ44219821-961F522A-A8FE-4C85-AC56-E296F77FEFF8Q51737577-CD0B8A7F-140A-4CAA-95B3-A2C827A6CBD5Q53228641-6C93F379-E953-477C-9013-9BCC616FF8D1Q57149637-4F3464BE-84F3-4B85-A428-D18F07A2845AQ58744597-53E7540A-F150-4D8D-B5DE-C7A369BD22A7
P2860
Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@ast
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@en
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@nl
type
label
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@ast
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@en
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@nl
prefLabel
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@ast
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@en
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@nl
P2093
P2860
P1433
P1476
Farnesoid X receptor activatio ...... e with chronic kidney disease.
@en
P2093
Adelheid Kratzer
Linda B Lewis
Makoto Miyazaki
Moshe Levi
Shinobu Miyazaki-Anzai
Tabitha C Ting
P2860
P304
P356
10.1161/CIRCRESAHA.109.212969
P577
2010-04-29T00:00:00Z